LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

Breast Cancer Clinical Trial

Official title:

A Phase I, Open-label, Multi-arm, Multi-centre, Multi-dose, Dose Escalation Study of LTX-315 as Monotherapy or in Combination With Either Ipilimumab or Pembrolizumab in Patients With Transdermally Accessible Tumours

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01986426
• Other study ID #: C12-315-03
• Status: Completed
• Phase: Phase 1
• Start date: November 2013
• Est. completion date: August 31, 2018

Study information

• Verified date: May 2018
• Source: Lytix Biopharma AS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will assess the safety, tolerability, PK and efficacy of different intra-tumoral dosing regimens of LTX-315; a lytic-peptide that induces long-term anti-cancer immune responses, as monotherapy or in combination with ipilimumab or pembrolizumab.

Description:

In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed.

Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions available.

Arm A: Single lesion/sequential lesion treatment arm (LTX-315 monotherapy) (Completed) Arm B:

Concurrent multiple lesion treatment arm with all tumour types (LTX-315 monotherapy) Arm C:

LTX-315 combination with ipilimumab in patients with melanoma Arm D: LTX-315 combination with pembrolizumab in patients with TNBC

All patients will have at least one lesion available for injection.

Treatment schedule:

Arm A: Injection of LTX-315 3 days week 1, 1 day in week 2, 3, 4, 5 and 6. Every 2 weeks starting with week 8.

Arm B (all tumours): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16).

Arm C (melanoma): Injection of lTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with ipilimumab given in week 1 and every 3 weeks 4 cycles.

Arm D (TNBC): Injection of LTX-315 2 days week 3 weeks (Day 1, 2, 8, 9, 15 and 16) in combination with pembrolizumab given in week 1 and every 3 weeks up to 2 years.

Patients will be enrolled into a dose cohort in order of study entry. Staring with the lowest dose. A minimum of 3 patients will be enrolled into each cohort. Dose escalation determined by the Safety Review Committee and the Sponsor. The the optimal regimen will be based on the results of the Dose Escalation from the following information:

1. Safety parameters including blood samples and cardiovascular effects

2. Immunohistology and ultrasound confirmation of necrosis and tumour infiltrating lymphocytes

3. Systemic inflammatory response

4. Evidence of clinical responses

Cohorts may be utilized to:

1. Evaluate different doses of LTX-315

2. Explore potential modifications to the dosing schedule

3. Evaluate the potential to include appropriate combination therapies with LTX-315

4. Gain further information on clinical efficacy

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: August 31, 2018
• Est. primary completion date: April 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Arm A: (Recruitment completed)

Arm B:

• Unresectable metastatic disease (any tumor type) and conventional anti-tumor treatment is not appropriate.

• Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection between 1-3 cm longest diameter and one bystander lesion (non-injected).

Arm C:

• Have unresectable/metastatic diagnosis of malignant melanoma (histologically confirmed).

• Have at least one available lesion (cutaneous, sub-cutaneous, oral or lymph node) for injection and biopsy which is between 1 and 3 cm in longest diameter.

• Have had previous treatment with an anti-PD-1 antibody (as monotherapy or as part of combination (any combination) as 1st or 2nd line metastatic treatment).

Arm D:

• Have unresectable/metastatic diagnosis of triple negative breast cancer (histologically confirmed).

• Have at least one available lesion (cutaneous, sub-cutaneous or lymph node) for injection and biopsy with a minimum longest diameter of 1 cm.

• Have received between one and 4 prior systemic treatments for metastatic triple negative breast cancer.

All arms:

• Be willing to undergo repeat tumour biopsy and/or tumour resection procedures.

• Have an ECOG Performance status (PS): 0 - 1.

• Meet the following laboratory requirements:

1. Absolute neutrophil count (ANC) = 1.5 x 109/L

2. Absolute lymphocyte count = 0.8 x 109/L

3. Platelet count = 75 x 109/L

4. Haemoglobin = 9.0 g/dL

5. aPTT/PT within the institution's normal range

6. Total bilirubin level = 1.5 x ULN

7. ASAT and ALAT = 2.5 x ULN (=5 x ULN if liver metastasis present)

8. Creatinine = 1.5 x ULN

9. Albumin = 30 g/L

Exclusion Criteria:

Arm A: (Completed)

Arm B:

• Have a history of systemic auto-immune disease requiring anti-inflammatory or immunosuppressive therapy within the last 3 months. Patients with history of autoimmune thyroiditis are eligible provided the patient requires only thyroid hormone replacement therapy and disease has been stable for = 1 year.

Arm C:

• Have had prior therapy with ipilimumab or any other anti-CTLA-4 monoclonal antibody.

• Have had BRAF/MEK inhibitors administered within 2 weeks prior to the study drug administration.

• Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; have a history of severe immune-related adverse reaction from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.

Arm D:

• Have had prior therapy with an anti-PD-1 or anti-PD-L1 monoclonal antibody.

• Have received cancer immunotherapy within 2 weeks prior to study drug administration or have not recovered from adverse events (to = CTCAE grade 1) due to such agents.

• Have active systemic autoimmune disease; have had prior pneumonitis; have a history of severe hypersensitivity to another monoclonal antibody; are receiving immunosuppressive therapy; and have a history of severe immune-related adverse reactions from treatment with a monoclonal antibody, defined as any Grade 4 or 3 toxicity requiring corticosteroid treatment (> 10 mg/day prednisone or equivalent) for greater than 12 weeks.

All arms:

• Have received external radiotherapy or cytotoxic chemotherapy within 4 weeks prior to study drug administration, or have not recovered from adverse events (= CTCAE grade 1) due to agents administered more than 4 weeks earlier. Palliative radiotherapy to non-target lesions within 4 weeks prior to study drug administration is allowed.

• Are currently taking any agent with a known effect on the immune system. Patients are allowed to be on a stable dose of corticosteroids (up to 10 mg daily prednisolone or equivalent) for at least 2 weeks prior to study drug administration (please see Appendix IV for prohibited medications).

• Have any other serious illness or medical condition such as, but not limited to:

1. Uncontrolled infection or infection requiring antibiotics

2. Uncontrolled cardiac failure: Classification III or IV (New York Heart Association)

3. Uncontrolled systemic and gastro-intestinal inflammatory conditions

4. Bone marrow dysplasia

• Have a known history of positive tests for HIV/AIDS, or have active hepatitis B or C (based on serology).

• Are expected to need any other anti-cancer therapy or immunotherapy to be initiated during the study period.

15. Have clinically active or unstable CNS metastases as assessed by the treating physician.

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Cancer
• Head and Neck Cancer
• Head and Neck Neoplasms
• Lymphoma
• Melanoma
• Triple Negative Breast Neoplasms
• Triple-Negative Breast Cancer

Intervention

Drug:
• LTX-315 consecutive lesions
Dose escalation: Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)
• LTX-315
Dose escalation: Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection
• LTX-315 + ipilimumab
Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
• LTX-315 + pembrolizumab
Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab

Locations

Country	Name	City	State
Belgium	Cliniques Universitaires St-Luc, Service d'oncologie médicale	Bruxelles
Belgium	Jules Bordet Institute	Bruxelles
France	Institut Curie	Paris
France	Institute Gustave Roussy	Paris
Italy	Intotuto Europeo di Oncologia (IEO)	Milano
Italy	San Raffaele Hospital	Milano
Italy	Intituto Nazionale dei Tumori	Napoli
Italy	Instituto Oncologico Venneto (IOV)	Padova
Norway	Haukeland University Hospital	Bergen
Norway	Oslo University Hospital Radiumhospitalet	Oslo
United Kingdom	Guy's Hospital	London
United Kingdom	Royal Marsden Hospital	London
United Kingdom	University College of London Hospital	London
United Kingdom	Christie Hospital NHS Foundatin Trust	Manchester

Sponsors (3)

Lead Sponsor	Collaborator
Lytix Biopharma AS	ICON plc, Theradex

Countries where clinical trial is conducted

Belgium,  France,  Italy,  Norway,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Pharmacokinetic (PK) profile of LTX-315	Measurement of plasma concentrations of LTX-315 pre- and 1 hour post-dosing day 2 in week 1.	Pre and 1 hour post dosing Day 2 Week 1
Primary	Dose limiting toxicity	Dose limiting toxicities (DLT) and the overall safety profile (adverse events (AE), laboratory assessments, physical findings and symptomatic assessment) of LTX-315 as monotherapy and in combination with ipilimumab or pembrolizumab.	21 days
Secondary	Anti tumour activity in injected tumour	Number of patients with regression of injected tumour assessed by ultrasound and/or CT/MRI.	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Secondary	Complete response (irCR) and partial response (irPR)	Number of patients by irRC	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Secondary	Overall response rate (OR)	(irRC criteria)	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Secondary	Disease control rate (CR + PR + SD)	irRC criteria	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed
Secondary	Progression free survival (PFS)	irRC criteria	Every 8 weeks from treatment start up to 24 months or first documented progression documented assessed